Treatment of BRCA1/2 Hereditary Breast Cancer and Sporadic Breast Cancer with Poly(ADP-ribose) PARP-1 Inhibitors and Chemotherapy

摘要

This year it is estimated that there will be over 250,000 new cases of breast carcinoma in situ and invasive breast cancer with an accompanying 40, 000 deaths. Current therapies to treat breast cancer are relatively non- specific and highly toxic. There is an urgent need to develop safe and effective therapies for the therapeutic treatment of breast cancer. In this study, we looked at a new class of relatively non-toxic compounds called PARP-1 inhibitors and evaluated the use of these compounds in concert with standard chemotherapy and other therapeutic agents to treat both sporadic and hereditary breast cancer using a phased strategy from our statement of work: Task I: Dose response curves, Task II: In vivo mouse model allografts, Task III: In vivo mouse model xenografts, Task IV: Inhibition of Development of mammary tumor and Task V: Publication and presentation of results. We challenged standard concepts and use out of the box thinking to move forward the fight against breast cancer.